A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Inclusion Criteria

• •Adult patient \>/= 18 years of age
• •Malignant melanoma (Stage IV, AJCC)
• •Patients who are treatment-naive or have received prior systemic treatments for metastatic melanoma. Time elapsed between previous treatment for metastatic disease and first administration of study drug must be at least 28 days
• •Positive tested for BRAF mutation
• •Patients must not be poor metabolizers of CYP450 enzymes 2C9, 2C19, or 2D6 as determined by genotyping
• •Measurable disease by RECIST criteria
• •Negative pregnancy test; for fertile men and women, effective contraception during treatment and for 6 months after completion